Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.38 -0.91 (-3.09%)

Delayed Quote Updated: 3:59 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Here Are My Top 4 Stocks to Buy in October ↗

October 05, 2026

Get 'em while they're still on sale. Catalysts are on the horizon.

Via The Motley Fool

Topics Artificial Intelligence

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? ↗

October 02, 2026

The weight loss drug company continues to make progress, but its share price is bouncing around with events.

Via The Motley Fool

Prediction: This Stock Could Double Over the Next 5 Years ↗

October 02, 2026

The obesity drug market is so large that only a small market share could lead to substantive price appreciation for the stock.

Via The Motley Fool

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗

September 30, 2026

Could this be what Novo needs to turn things around?

Via The Motley Fool

Topics Initial Public Offering

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. ↗

September 30, 2026

There could be more catalysts for the biotech over the next 18 months.

Via The Motley Fool

3 Emerging Biotech Stocks With Significant Upside Potential ↗

September 30, 2026

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Via MarketBeat

Topics Intellectual Property

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. ↗

September 29, 2026

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Via The Motley Fool

3 Non-AI Growth Stocks That Have Massive Upside ↗

September 29, 2026

Investors looking for some compelling growth opportunities outside of tech may want to consider these stocks.

Via The Motley Fool

Topics Artificial Intelligence

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? ↗

September 28, 2026

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Via The Motley Fool

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution ↗

September 27, 2026

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

Via The Motley Fool

3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing ↗

September 27, 2026

The company continues to make good progress with its key obesity treatment drug, VK2735.

Via The Motley Fool

MarketBeat Week in Review – 09/21 - 09/25 ↗

September 26, 2026

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

Via MarketBeat

Topics Artificial Intelligence Bonds Economy

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗

September 25, 2026

The biotech player could eventually rival big pharma companies.

Via The Motley Fool

Here's Why Viking Therapeutics Shares Slumped Today ↗

September 24, 2026

It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.

Via The Motley Fool

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗

September 23, 2026

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Via The Motley Fool

Which stocks are experiencing notable movement on Tuesday? ↗

September 22, 2026

Via Chartmill

What's going on in today's session ↗

September 22, 2026

Via Chartmill

Gapping stocks in Tuesday's session ↗

September 22, 2026

Via Chartmill

Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing ↗

September 22, 2026

Viking Therapeutics (NASDAQ:VKTX) reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much...

Via MarketBeat

Tuesday's pre-market session: top gainers and losers ↗

September 22, 2026

Via Chartmill

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗

September 17, 2026

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Via The Motley Fool

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗

September 14, 2026

Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13...

Via MarketBeat

Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September ↗

September 11, 2026

Both companies are approaching milestones that could light a fire under their stocks.

Via The Motley Fool

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.

Via The Motley Fool

Topics Intellectual Property

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗

September 10, 2026

This company aims to serve a market heading toward $100 billion.

Via The Motley Fool

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗

September 05, 2026

Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.

Via The Motley Fool

3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong ↗

September 03, 2026

Viking Therapeutics deserves a second look, but some analysts are a bit too optimistic.

Via The Motley Fool

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. ↗

August 30, 2026

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

Via The Motley Fool

Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? ↗

August 27, 2026

Investor sentiment on the key benefit of its lead drug candidate could be impacted in the current quarter.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.